Targeted quantitative proteomics is closed-panel protein measurement in which predefined proteotypic peptides are selectively acquired and converted into quantitative values on liquid chromatography-tandem mass spectrometry (LC-MS/MS). Multiple reaction monitoring (MRM) or selected reaction monitoring (SRM) records scheduled precursor-to-product transitions (Lange et al. 2008). Parallel reaction monitoring (PRM) isolates scheduled precursors and stores high-resolution product-ion spectra for fragment review (Peterson et al. 2012). The quantitative claim is not created by instrument brand. It is created by a frozen target list, selective acquisition, and a declared relative or absolute reporting rule.

Relative targeted values answer fold-change or panel-comparison questions under a stated normalization rule. Absolute values answer amount questions only when matched stable isotope-labeled internal standard (SIS) peptides or Absolute QUAntification (AQUA) design and a valid calibration model are documented (Gerber et al. 2003; Carr et al. 2014). Surrogate peptides report the measured sequence under the stated digest. They do not invent every isoform or modified form by default (Bantscheff et al. 2012). Discovery profiling can nominate candidates, but it is not the same quantitative object as a locked targeted table.

In MtoZ Biolabs targeted offerings, quantitative scope is set when list status, claim unit, matrix notes, and quality control (QC) depth are written in the brief. Service intake appears in Targeted Proteomics Service.

What Targeted Quantitative Proteomics Means

Four definition layers belong in the brief and stay separated.

Target layer names the proteins or peptides before acquisition. If the list is still open, the study is still discovery work.

Acquisition layer spends instrument time only on the closed panel through MRM/SRM transitions or PRM fragment spectra.

Quantitation layer converts peak areas into relative ratios or SIS-calibrated amounts under a declared rule.

Claim layer states what the numbers are allowed to support: group contrast, panel confirmation, or concentration reporting. Clinical diagnosis or release language needs a separately validated method beyond a research table.

Targeted quantitative proteomics means remeasuring known surrogates under a declared claim unit. Sensitivity slogans alone do not define the method.

How Relative and Absolute Targeted Quantitation Differ

Both are targeted when the peptide list is closed. They are not the same claim.

Relative quantitation compares the same peptide across samples after matched preparation and a declared normalization strategy. It supports fold-change and panel trends when QC and peak evidence pass. It does not become concentration by renaming peak areas.

Absolute quantitation introduces a known SIS or AQUA amount and a calibration model so reporting units such as ng/mL or fmol can be assigned inside a validated range (Gerber et al. 2003). Spike timing, matrix matching, and QC recovery belong in the method record (Carr et al. 2014). Absolute versus relative route framing appears in Absolute Protein Quantification or Relative Quantitation? Matching AQUA, MRM/PRM, and Label-Free Routes to Your Reporting Goal. Absolute service intake appears in Absolute Quantitative Analysis (AQUA) Service.

MRM and PRM are acquisition modes that can carry either claim. Platform choice depends on transition stability and fragment-review need, not on whether the word quantitative appears in the title. Method-family boundaries appear in Overview of Targeted Proteomics: Methods, Techniques, Key Points, and Applications. Platform fit appears in Parallel Reaction Monitoring vs MRM: Which Fits?.

End-to-End Workflow From Closed List to Quantitative Table

A practical quantitative spine usually runs as follows.

1. Freeze the decision: relative group contrast, panel confirmation, or absolute amount.
2. Close the protein or peptide list and assign a panel version ID.
3. Select proteotypic surrogates that are unique, detectable, and stable under the planned digest.
4. Declare relative normalization or SIS/AQUA absolute rules, including spike timing when absolute units are required.
5. Choose MRM/SRM, PRM, or a hybrid design from matrix risk and fragment-review need.
6. Match extraction, digest, cleanup, and load across every contrast arm.
7. Build and pilot the selective method on matrix-matched digests before full cohort shipment.
8. Acquire interleaved study samples with blanks, QC pools, and calibrators when absolute units are required.
9. Integrate peaks, apply inclusion rules, flag failed targets, and deliver tables with method notes and the declared reporting unit.

Steps 1 through 4 protect the quantitative definition. Steps 5 through 9 are the assay, acquisition, and reporting record. MRM/SRM service context appears in SRM-MRM Quantitative Proteomics Services. PRM service context appears in Parallel Reaction Monitoring (PRM) Service. Discovery-to-targeted staging appears in Targeted Mass Spectrometry or Discovery LC-MS/MS? Matching MRM, PRM, and Profiling Routes to Your Analytical Goal.

Figure 1. Targeted quantitative proteomics converts a closed surrogate panel into relative or absolute values only after claim unit and QC rules are locked.

Parameters That Must Be Declared for a Quantitative Claim

Layer	Parameter that must be declared	Failure mode if ignored
Decision	Relative contrast versus absolute unit	Wrong evidence applied to the claim
Panel version	Closed peptide list ID	Mid-study target growth
Surrogate	Uniqueness and digest rules	Protein-level overclaim
Acquisition	MRM/SRM, PRM, or hybrid	Interference unread
Normalization	Relative rule and internal standard behavior	Batch comparison without a common scale
Calibration	SIS or AQUA design, range, matrix matching	Peak areas read as concentrations
Prep parity	Matched digest and cleanup across arms	Prep drift read as biology
QC plan	Blanks, pools, precision, drift checks	Failed batches accepted
Inclusion rules	Failed-target handling	Silent zeros in group means
Deliverable	Reporting unit archived with the table	Numeric file without claim context

Limits follow the same table. Targeted quantitative methods cannot quantify unnamed proteins without peptide selection. Higher sensitivity for a closed panel does not create discovery coverage. Absolute wording without SIS design remains a relative assay. Clinical or batch-release language needs a quality system beyond a research quantitative table.

What Targeted Quantitative Results Can Support

A QC-supported relative table supports same-peptide comparison across samples acquired with one locked method. A QC-supported absolute table supports concentration or amount for surrogates inside the calibrated interval.

Panel confirmation and pathway contrasts are fit cases after inclusion rules pass. Failed targets support exclusion or redesign. They do not support silent zeros. Cross-study comparison needs matching normalization or calibration assumptions.

A targeted quantitative value supports a declared claim unit. It does not convert discovery candidates into validated clinical cutoffs by itself.

How to Choose Relative, Absolute, or Discovery First

Use list status, claim unit, and matrix readiness together.

Project signal	Quantitative path that often fits	Recheck before committing
Closed panel, fold-change decision	Relative MRM or PRM with declared normalization	Call ratios concentrations
Closed panel, amount decision	SIS or AQUA design plus calibrators	Relative-only method for ng/mL claims
Interference-limited peptides	PRM or hybrid after matrix pilot	Force weak MRM for absolute claims
List still open	Discovery DDA or DIA first	Targeted quote on unnamed proteins
Need method and QC notes	Deliverables locked before acquisition	Interpret tables without reporting unit
Heavy standard or curve failing	Troubleshoot before cohort expansion	Scale a weak absolute method

Figure 2. Choose relative or absolute targeted quantitation from the decision unit; keep discovery first when the protein list is still open.

Results review after delivery belongs on Reading Targeted Mass Spectrometry Results with Confidence. Teams with closed peptide lists, claim units, and QC plans can review MtoZ Biolabs Targeted Proteomics Service when those fields are declared in the project record.

Frequently Asked Questions

1. What is targeted quantitative proteomics in one sentence?

It is selective LC-MS/MS measurement of predefined proteotypic peptides that produces relative or absolute quantitative values under a declared reporting rule.

2. Does targeted always mean absolute quantification?

No. Targeted describes the closed list and selective acquisition. Absolute units require SIS or AQUA design and calibration. Relative targeted panels remain quantitative for fold-change decisions.

3. How is targeted quantitative proteomics different from discovery proteomics?

Discovery profiles an open or semi-open proteome to find candidates. Targeted quantitative proteomics remeasures a closed panel with selective acquisition and a declared claim unit.

4. Are MRM and PRM required for targeted quantitation?

They are the common acquisition modes. Either can support relative or absolute claims when the panel, QC, and reporting rules are locked.

5. What must be locked before calling a dataset targeted quantitative?

A versioned peptide list, acquisition mode, matched prep, claim unit, QC plan, and deliverable list that states the reporting unit.

MtoZ Biolabs can provide targeted quantitative proteomics using MRM, PRM, and isotope-assisted absolute quantification for predefined protein or peptide panels, including QC-supported relative or absolute reporting when study goals are documented.

If further evaluation of relative versus absolute claim design, MRM versus PRM acquisition, or discovery-to-targeted staging is needed, project details can be submitted for a feasibility review.

Reference

1. V. Lange, P. Picotti, B. Domon, R. Aebersold (2008). Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol., 4, 222. https://doi.org/10.1038/msb.2008.61
2. A.C. Peterson, J.D. Russell, A.A. Klammer, P.F. Doubleday, H. Liu, J.N. Anderson, M.J. MacCoss (2012). Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics, 11, 1475-1488. https://doi.org/10.1074/mcp.O112.020271
3. S.A. Gerber, J. Rush, O. Stemman, M.W. Kirschner, S.P. Gygi (2003). Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U.S.A., 100, 6940-6945. https://doi.org/10.1073/pnas.0832254100
4. S.A. Carr, S.E. Abbatiello, B.L. Ackermann, C. Borchers, B. Domon, E.W. Deutsch, R.P. Grant, A.N. Hoofnagle, R. Huttenhain, J.M. Koomen, D.C. Liebler, T. Liu, B. MacLean, D.R. Mani, E. Mansfield, H. Neubert, A.G. Paulovich, L. Reiter, O. Vitek, R. Aebersold, A.J. Smith, et al. (2014). Targeted peptide measurements in biology and medicine: best practices for sample preparation, assay standardization, and assay validation. Mol. Cell. Proteomics, 13, 907-917. https://doi.org/10.1074/mcp.M113.036095
5. M. Bantscheff, S. Lemeer, H.U. Haab, B. Kuster (2012). Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem., 404, 939-965. https://doi.org/10.1007/s00216-012-5892-4